Pharmaceutical Industry Reports Botanical and Plant Derived Drugs Market - Size, S | Page 2

REPORT DESCRIPTION
Botanical and Plant Derived Drugs Market – Overview
In several diseases, there is no cure for chronic pain. Therefore, physicians prefer pharmacologic methods to treat
pain and decrease the suffering of patients. Patients suffering from intractable chronic pain, which cannot be
managed with conventional treatment methods, prefer botanical and plant derived drugs. Lung cancer is the
leading cause of death in the Eastern, Southern, and Southeastern Asia.
According to the 2013- International Agency for Research on Cancer data, in 2012, 1,033,881 cases of lung
cancer occurred only in Asia. In addition, Eastern, Southern, and Southeastern Asia region accounts for 56% of
the world’s population and contributes to 44% of the total cancer cases, worldwide according to the statistics
mentioned in The Cancer Atlas. High cost of developing and manufacturing conventional drugs is propelling
demand for alternative solution, such as plant-derived drugs that cost less than conventional drugs.
Requirement of less technical experts and low capital investment for manufacturing botanical and plant-derived
drugs. For instance, in October 2016, Napo Pharmaceuticals, Inc. launched Mytesi, an antidiarrheal indicated for
the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on Antiretroviral Therapy
(ART).